Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BYSI | 8-K | neutral | 4/10 | BeyondSpring reported Q1 2026 financial results with a net loss from continuing operations of $2.4M, slightly improved f | May 13, 2026 |
| VERU | 8-K | neutral | 4/10 | Veru reported fiscal Q2 2026 net loss of $2.7M (-$0.12/share) vs $7.9M (-$0.54/share) a year ago, beating the $-0.37 con | May 13, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 4/10 | Zenas BioPharma announced first subject dosed in Phase 1 trial of ZB021, an oral IL-17AA/AF inhibitor for autoimmune dis | May 13, 2026 |
| APRE | 8-K | bullish | 7/10 | Aprea Therapeutics reported Q1 2026 results with a net loss of $3.3M ($0.22/share), narrower than the $3.9M loss in Q1 2 | May 13, 2026 |
| VERU | PRESS-RELEASE | neutral | 5/10 | Veru reported Q2 2026 net loss of $2.7M ($0.12/share), narrower than the $7.9M loss a year ago, driven by lower R&D and | May 13, 2026 |
| APRE | PRESS-RELEASE | neutral | 5/10 | Aprea Therapeutics reported Q1 2026 EPS of -$0.22 (GAAP), beating the -$0.23 consensus by 4.3%, but the headline EPS mis | May 13, 2026 |
| ZBIO | 8-K | neutral | 4/10 | Zenas BioPharma reported Q1 2026 results: net loss widened to $81.0M from $33.6M a year ago, with zero revenue vs $10M i | May 13, 2026 |
| TKPHF | 6-K | neutral | 2/10 | Takeda filed a 6-K announcing the continuation of its stock compensation plan for directors and stock grant system for m | May 13, 2026 |
| BIAFW | EFFECT | neutral | 3/10 | The SEC declared effective the resale registration statement (S-1, File No. 333-295465) for bioAffinity Technologies, In | May 13, 2026 |
| TVRD | EFFECT | bearish | 7/10 | Tvardi Therapeutics' S-3 registration statement has been declared effective, allowing the company to sell up to $200 mil | May 13, 2026 |
| ELAB | 8-K | mixed | 7/10 | PMGC Holdings (ELAB) acquired 100% of A&B Aerospace, a precision CNC machining contractor, for $4.8M in cash ($4.275M at | May 13, 2026 |
| TRAX | EFFECT | neutral | 4/10 | First Tracks Biotherapeutics' S-1 registration (333-295719) became effective on May 12, 2026, covering the resale of up | May 13, 2026 |
| VYGR | PRESS-RELEASE | bullish | 6/10 | Voyager Therapeutics presented positive 3-month GLP toxicology data for VY1706, a tau-silencing gene therapy for Alzheim | May 13, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 5/10 | Zenas BioPharma reported Q1 2026 net loss of $81.0M ($1.46/share), significantly wider than the $33.6M loss a year ago, | May 13, 2026 |
| ELAB | PRESS-RELEASE | neutral | 5/10 | PMGC Holdings acquired A&B Aerospace for $4.5M in cash, marking its fifth acquisition in 12 months as part of a roll-up | May 13, 2026 |
| GNLX | CLUSTER | neutral | 2/10 | Two insiders at Genelux Corp sold a total of $9K in open-market sales on May 11, 2026, including the CEO and Head of Reg | May 12, 2026 |
| PTGX | CLUSTER | neutral | 5/10 | CEO Dinesh Patel and Director Bryan Giraudo sold a combined $11.7M in open-market shares within a week of PTGX reporting | May 12, 2026 |
| HOWL | CLUSTER | bearish | 6/10 | Two insiders at Werewolf Therapeutics sold a total of $299K in open-market sales over a 7-day window, representing ~0.9% | May 12, 2026 |
| XFOR | 144 | neutral | 2/10 | David Kirske, an officer of X4 Pharmaceuticals, filed a Form 144 notice of intent to sell 16,961 shares of common stock | May 12, 2026 |
| ODTX | CLUSTER | bullish | 7/10 | Odyssey Therapeutics insiders, including Director Li Nan and Director Chu Shelley, made open-market purchases totaling ~ | May 12, 2026 |
| PTGX | 144 | bearish | 5/10 | CEO Dinesh Patel filed a Form 144 to sell 75,000 shares (~$7.76M at the filing date) via J.P. Morgan. This is a material | May 12, 2026 |
| PALI | S-3 | neutral | 5/10 | Palisade Bio filed a $300M universal shelf registration statement on Form S-3, concurrent with its Q1 2026 earnings rele | May 12, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three top executives at United Therapeutics (CEO, CFO, General Counsel) executed option exercises and sold a portion of | May 12, 2026 |
| RIGL | 8-K | bullish | 7/10 | Rigel Pharmaceuticals entered into a worldwide exclusive license agreement with Arvinas and Pfizer for VEPPANUTM (vepdeg | May 12, 2026 |
| RDY | 6-K | neutral | 3/10 | Dr. Reddy's Laboratories filed its Q4 FY26 audited financial results presentation via a 6-K on May 12, 2026. The filing | May 12, 2026 |
| SAFX | 8-K | bearish | 8/10 | XCF Global settled $16.7M in accounts payable and property liens owed to Encore DEC (owned by majority shareholder Randy | May 12, 2026 |
| BBOT | PRESS-RELEASE | neutral | 4/10 | BBOT reported Q1 2026 net loss of $42.1M vs $22.1M a year ago, with R&D spend nearly doubling to $39.8M as three clinica | May 12, 2026 |
| CSCIF | 6-K | mixed | 7/10 | COSCIENS Biopharma reported Q1 2026 results showing a net loss from continuing operations of $0.2 million, a significant | May 12, 2026 |
| MLYS | 144 | neutral | 2/10 | Officer David Malcom Rodman filed a Form 144 to sell 6,348 shares of Mineralys Therapeutics (MLYS) valued at approximate | May 12, 2026 |
| EPRX | PRESS-RELEASE | neutral | 4/10 | Eupraxia reported a Q1 2026 net loss of $12.7M (vs $6.8M a year ago), with cash and short-term investments totaling $138 | May 12, 2026 |